Literature DB >> 16217072

CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases.

J C Reijneveld1, D Brandsma, W Boogerd, J G M Bonfrer, S Kalmijn, E E Voest, A Geurts-Moespot, M C Visser, M J B Taphoorn.   

Abstract

The authors determined the levels of vascular endothelial growth factor (VEGF) and urokinase-type plasminogen activator (uPA) in the CSF of patients with leptomeningeal metastases (LM; n = 53), cancer patients without LM (n = 18), and subjects without malignancy (n = 25). Median levels of uPA and VEGF were significantly higher in patients with LM, supporting the hypothesis that angiogenesis contributes to LM. VEGF was negatively correlated with survival in patients with LM, suggesting its use as a prognostic factor.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16217072     DOI： 10.1212/01.wnl.0000178981.39984.c2

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  14 in total

Review 1.  Breast leptomeningeal disease: a review of current practices and updates on management.

Authors:  Nicholas B Figura; Victoria T Rizk; Avan J Armaghani; John A Arrington; Arnold B Etame; Hyo S Han; Brian J Czerniecki; Peter A Forsyth; Kamran A Ahmed
Journal:  Breast Cancer Res Treat       Date:  2019-06-17       Impact factor: 4.872

Review 2.  Novel methods to diagnose leptomeningeal metastases in breast cancer.

Authors:  Lindsay Angus; John W M Martens; Martin J van den Bent; Peter A E Sillevis Smitt; Stefan Sleijfer; Agnes Jager
Journal:  Neuro Oncol       Date:  2019-03-18       Impact factor: 12.300

3.  CSF protein profiling using Multiplex Immuno-assay: A potential new diagnostic tool for leptomeningeal metastases.

Authors:  Dieta Brandsma; Emile E Voest; Wilco de Jager; Hans Bonfrer; Ale Algra; Willem Boogerd; Tiny Korse; Jaap C Reijneveld; Marcel M Verbeek; Ger Rijkers; Martin J B Taphoorn
Journal:  J Neurol       Date:  2006-09-22       Impact factor: 4.849

4.  Contrast-Enhancing Meningeal Lesions Are Associated with Longer Survival in Breast Cancer-Related Leptomeningeal Metastasis.

Authors:  Anne Constanze Regierer; Andrea Stroux; Dagmar Kühnhardt; Annette Dieing; Silvia Lehenbauer-Dehm; Bernd Flath; Kurt Possinger; Jan Eucker
Journal:  Breast Care (Basel)       Date:  2008-04-15       Impact factor: 2.860

Review 5.  Neuro-ophthalmologic complications of neoplastic leptomeningeal disease.

Authors:  Gabriella Szatmáry
Journal:  Curr Neurol Neurosci Rep       Date:  2013-12       Impact factor: 5.081

Review 6.  Advances in the Diagnosis and Treatment of Leptomeningeal Disease.

Authors:  Akanksha Sharma; Justin T Low; Priya Kumthekar
Journal:  Curr Neurol Neurosci Rep       Date:  2022-05-19       Impact factor: 5.081

7.  CSF CA 15-3 in breast cancer-related leptomeningeal metastases.

Authors:  Emilie Le Rhun; Andrew Kramar; Sophie Salingue; Marie Girot; Isabelle Rodrigues; Audrey Mailliez; Fahed Zairi; Edgar Bakhache; Yves Marie Robin; Sophie Taillibert; François Dubois; Jacques Bonneterre; Marc C Chamberlain
Journal:  J Neurooncol       Date:  2014-01-28       Impact factor: 4.130

8.  Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma.

Authors:  Morris D Groves; Kenneth R Hess; Vinay K Puduvalli; Howard Colman; Charles A Conrad; Mark R Gilbert; Jeffrey Weinberg; Massimo Cristofanilli; W K Alfred Yung; Ta-Jen Liu
Journal:  J Neurooncol       Date:  2009-03-07       Impact factor: 4.130

9.  Treatment of leptomeningeal spread of NSCLC: a continuing challenge.

Authors:  Seema Nagpal; Jonathan Riess; Heather Wakelee
Journal:  Curr Treat Options Oncol       Date:  2012-12

10.  Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors.

Authors:  Lakshmi Nayak; Martin Fleisher; Rita Gonzalez-Espinoza; Oscar Lin; Katherine Panageas; Anne Reiner; Chhui-Mei Liu; Lisa M Deangelis; Antonio Omuro
Journal:  Neurology       Date:  2013-04-03       Impact factor: 9.910
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.